atopic dermatitis
Dermatology · 2006–2026
23decisions
10medicines
21carried consumer input
704individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nemolizumab Treatment of patients aged 12 years or older with chronic severe atopic dermatitis affecting the whole body, face, and/or hands, who are inadequately… | Mar 2026 | Recommended with restriction | 1 individuals Australian Society of Clinical Immunology and Allergy · Anaphylaxis Australia · National Allergy Council |
| nemolizumab Treatment of patients aged 12 years or older with chronic severe atopic dermatitis affecting the whole body, face, and/or hands, who are inadequately… | Jul 2025 | Not recommended | input received Eczema Support Australia · Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council |
| tacrolimus Treatment of moderate to severe atopic dermatitis in patients aged 16 years and older who have failed to achieve satisfactory disease control with topical… | Jul 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| tacrolimus Treatment of moderate to severe atopic dermatitis in patients aged 16 years and older who have failed to achieve satisfactory disease control with topical… | Jul 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| dupilumab Treatment of chronic severe atopic dermatitis in paediatric patients aged less than 12 years, and uncontrolled severe asthma in paediatric patients aged 6 to… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| dupilumab Treatment of severe atopic dermatitis in patients aged 12 years and older. | Jul 2024 | Not recommended | input received |
| lebrikizumab Treatment of severe atopic dermatitis in patients aged 12 years or older with inadequate control on topical therapies, affecting either the whole body or the… | Mar 2024 | Recommended with restriction | 5 individuals Eczema Association of Australasia Inc · Eczema Support Australia · Anaphylaxis Australia · National Allergy Council |
| abrocitinib Treatment of adult patients with chronic severe atopic dermatitis who are unable to achieve disease control with daily use of topical treatments for at least… | Nov 2024 | Recommended with restriction | 4 individuals Eczema Support Australia |
| dupilumab Severe atopic dermatitis in patients aged 12 years or older. This is a resubmission to revise utilisation estimates and risk sharing arrangement caps following… | Jul 2023 | Recommended with restriction | input received Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy · Eczema Support Australia |
| dupilumab, upadacitinib Treatment of severe atopic dermatitis in patients aged 12 years and older. | Nov 2023 | Noted | 1 individuals |
| dupilumab Severe chronic atopic dermatitis in patients aged 12 years or older who are uncontrolled on topical corticosteroids or for whom topical corticosteroids are… | Jul 2022 | Noted | input received Anaphylaxis Australia · Eczema Support Australia |
| dupilumab Treatment of children aged 6 to 11 years with severe atopic dermatitis who have had an inadequate response to topical therapies. | Mar 2022 | Recommended with restriction | 60 individuals Australasian Society of Clinical Immunology and Allergy · Anaphylaxis Australia · Eczema Support Australia |
| dupilumab Chronic severe atopic dermatitis and uncontrolled severe asthma in patients aged 12 years and older (autoinjector form); the pre-filled syringe form is… | Nov 2022 | Recommended | input received Asthma Australia |
| baricitinib Initial and continuing treatment of adults with severe atopic dermatitis who have failed to achieve an adequate response to topical corticosteroids and/or… | Jul 2021 | Not recommended | 13 individuals Eczema Support Australia · Anaphylaxis Australia · Both Eczema Support Australia |
| upadacitinib Initial and continuing treatment of adults and adolescents aged 12 years or older with severe atopic dermatitis affecting the whole body or face and hands,… | Jul 2021 | Deferred | 10 individuals Eczema Association of Australasia Inc · Eczema Support Australia · Anaphylaxis Australia · Both Eczema Support Australia |
| dupilumab Treatment of severe atopic dermatitis in adult patients who are inadequately controlled on topical therapies. | Mar 2020 | Recommended with restriction | 323 individuals Anaphylaxis Australia · Eczema Association of Australasia Inc · Eczema Support Australia |
| crisaborole Mild to moderate atopic dermatitis in patients aged ≥2 years who have failed to achieve satisfactory disease control with, are contraindicated to, or… | Nov 2020 | Not recommended | 3 individuals |
| dupilumab Treatment of patients aged 12 years and older with severe atopic dermatitis inadequately controlled on topical therapies. | Nov 2020 | Recommended with restriction | 71 individuals Eczema Association of Australia Inc · Eczema Support Australia |
| dupilumab Treatment of chronic moderate-to-severe atopic dermatitis in adult patients with inadequate response to topical therapies. | Jul 2019 | Not recommended | 159 individuals Anaphylaxis Australia · Eczema Association of Australasia Inc · Eczema Support Australia · Australasian Society of Clinical Immunology and Allergy |
| dupilumab Treatment of severe atopic dermatitis in adults with inadequate response, intolerance, or contraindication to cyclosporin A. | Jul 2018 | Not recommended | 54 individuals Anaphylaxis Australia · Eczema Association of Australasia · Australasian Society of Clinical Immunology and Allergy |
| crisaborole Treatment of mild to moderate atopic dermatitis in patients aged ≥2 years who are contraindicated to, have failed to achieve satisfactory disease control with,… | Nov 2018 | Not recommended | input received Eczema Association of Australasia and Hands |
| pimecrolimus Extension of listing to include treatment of patients with atopic dermatitis (facial or eyelid) who are at least 3 months of age, including adults over 18… | Jul 2006 | Recommended with restriction | no section in document |
| pimecrolimus Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with contraindications to topical corticosteroids, and short-term… | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
Anaphylaxis Australia · Eczema Support Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council · Eczema Association of Australasia Inc · Asthma Australia · Both Eczema Support Australia · Eczema Association of Australasia and Hands · Eczema Association of Australia Inc · Eczema Association of Australasia · Australian Society of Clinical Immunology and Allergy
What the PBS pays
$857M in government benefit over 2024–25, across 803,502 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| dupilumab | $490.8M |
| upadacitinib | $291.6M |
| tacrolimus | $42.1M |
| baricitinib | $31.3M |
| pimecrolimus | $1.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 8 technologies for this condition, recommending 6 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| nemolizumabNemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | recommended restricted | 2025-07 |
| lebrikizumabLebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | recommended restricted | 2024-07 |
| abrocitinib tralokinumab or upadacitinibAbrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | recommended restricted | 2022-08 |
| crisaboroleCrisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | terminated | 2021-05 |
| baricitinibBaricitinib for treating moderate to severe atopic dermatitis | TA681 | recommended restricted | 2021-03 |
| dupilumabDupilumab for treating moderate to severe atopic dermatitis | TA534 | recommended restricted | 2018-08 |
| frequency of application of topical corticosteroidsFrequency of application of topical corticosteroids for atopic eczema | TA81 | recommended restricted | 2004-08 |
| tacrolimus and pimecrolimusTacrolimus and pimecrolimus for atopic eczema | TA82 | not recommended | 2004-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 21 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.